insitro and Lilly team up to build models that predict how drug molecules behave in the body

insitro/ML-driven target discovery

insitro will train machine-learning models on Lilly's private preclinical data to predict how small molecules are absorbed, broken down and whether they are toxic. The models will be offered to other biotechs through Lilly's TuneLab platform, which keeps each partner's data separate.